United States

People: AcelRx Pharmaceuticals Inc (ACRX.O)

ACRX.O on Consolidated Issue listed on NASDAQ Global Market

22 Sep 2017
Change (% chg)

$0.15 (+4.69%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Hamel, Lawrence 

Mr. Lawrence G. Hamel is the Chief Development Officer of AcelRx Pharmaceuticals Inc., since September 2006. From 1986 until September 2006, Mr. Hamel served as Product Development Manager, Director Project Management, Executive Director Oral Product Development, and Vice President Oral Products Development at ALZA Corporation. From 1977 until 1985, Mr. Hamel held a number of other positions at ALZA Corporation, including Senior Chemist, Research Scientist, and Senior Research Fellow. Mr. Hamel holds a B.S. in Biology from the University of Michigan.

Basic Compensation

Total Annual Compensation, USD 1,069,670
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 7,800
Fiscal Year Total, USD 1,077,470

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --